Systematic Meta-Analysis Identifies Co-Expressed Kinases and GPCRs in Ovarian Cancer Tissues Revealing a Potential for Targeted Kinase Inhibitor Delivery

dc.accessRightsAnonymous*
dc.audienceScienceen_US
dc.contributor.authorAlbrecht, Hugo
dc.contributor.authorKübler, Eric
dc.date.accessioned2020-03-03T08:48:57Z
dc.date.available2020-03-03T08:48:57Z
dc.date.issued2019-09-02
dc.description.abstractThe use of many anticancer drugs is problematic due to severe adverse effects. While the recent clinical launch of several kinase inhibitors led to tremendous progress, these targeted agents tend to be of non-specific nature within the kinase target class. Moreover, target mediated adverse effects limit the exploitation of some very promising kinase targets, including mitotic kinases. A future strategy will be the development of nanocarrier-based systems for the active delivery of kinase inhibitors using cancer specific surface receptors. The G-protein-coupled-receptors (GPCRs) represent the largest cell surface receptor family and some members are known to be frequently overexpressed in various cancer types. In the presented study, we used ovarian cancer tissues as an example to systematically identify concurrently overexpressed GPCRs and kinases. The rationale of this approach will guide the future design of nanoparticles, which will dock to GPCRs on cancer cells via specific ligands and deliver anticancer compounds after receptor mediated internalization. In addition to this, the approach is expected to be most effective by matching the inhibitor profiles of the delivered kinase inhibitors to the observed kinase gene expression profiles. We validated the suggested strategy in a meta-analysis, revealing overexpression of selected GPCRs and kinases in individual samples of a large ovarian cancer data set. The presented data demonstrate a large untapped potential for personalized cancer therapy using high-end targeted nanopharmaceuticals with kinase inhibitors.en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pubmed/31480803en_US
dc.identifier.doi10.3390/pharmaceutics11090454.
dc.identifier.issn0378-5173
dc.identifier.issn1873-3476
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/30651
dc.issue9en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofPharmaceuticsen_US
dc.subjectGPCRen_US
dc.subjectcanceren_US
dc.subjectkinaseen_US
dc.subjectpersonalized medicineen_US
dc.subjecttargeted drug deliveryen_US
dc.titleSystematic Meta-Analysis Identifies Co-Expressed Kinases and GPCRs in Ovarian Cancer Tissues Revealing a Potential for Targeted Kinase Inhibitor Deliveryen_US
dc.type01A - Beitrag in wissenschaftlicher Zeitschrift
dc.volume11en_US
dspace.entity.typePublication
fhnw.InventedHereYesen_US
fhnw.IsStudentsWorknoen_US
fhnw.PublishedSwitzerlandYesen_US
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publicationen_US
fhnw.affiliation.hochschuleHochschule für Life Sciencesde_CH
fhnw.affiliation.institutInstitut für Chemie und Bioanalytikde_CH
fhnw.publicationOnlineJaen_US
fhnw.publicationStatePublisheden_US
relation.isAuthorOfPublication77be4b5b-df32-4082-89f5-d8e0b02cca6b
relation.isAuthorOfPublication.latestForDiscovery77be4b5b-df32-4082-89f5-d8e0b02cca6b
Dateien